Cigdem Usul Afsar1, Meral Gunaldı2, Yıldız Okuturlar3, Asuman Gedikbası4, Elif Eda Tiken5, Sibel Kahraman6, Feryal Karaca7, Vehbi Ercolak8, Mehmet Karabulut9. 1. Department of Medical Oncology, Istanbul Education and Research Hospital Istanbul, Turkey. 2. Department of Medical Oncology, Bakırkoy Dr Sadi Konuk Education and Research Hospital Istanbul, Turkey. 3. Department of Internal Medicine, Bakırkoy Dr Sadi Konuk Education and Research Hospital Istanbul, Turkey. 4. Department of Biochemistry, Bakırkoy Dr Sadi Konuk Education and Research Hospital Istanbul, Turkey. 5. Department of Radiation Oncology, Bakırkoy Dr Sadi Konuk Education and Research Hospital Istanbul, Turkey. 6. Department of Pathology, Bakırkoy Dr Sadi Konuk Education and Research Hospital Istanbul, Turkey. 7. Department of Radiation Oncology, Adana Numune Training and Research Hospital Adana, Turkey. 8. Department of Medical Oncology, Mersin Government Hospital Mersin, Turkey. 9. Department of General Surgery, Bakırkoy Dr Sadi Konuk Education and Research Hospital Istanbul, Turkey.
Abstract
BACKGROUND: The aim of this study was to evaluate paraoxonase-1 (PON1) and arylesterase (ARE) activities and oxidative stress status in patients with colorectal carcinomas (CRC). MATERIALS AND METHODS: Thirty-three patients (20 male, 13 female) with CRC and 30 healthy controls were enrolled in the study. Blood samples were obtained from the CRC patients before adjuvant therapy. Serum samples from CRC patients and healthy controls were analyzed for PON1 and ARE activities. RESULTS: The PON1 and ARE activities of the patients with CRC were significantly higher compared to those of the control group (PON1 activity is 125.35±20.07 U/L for CRC patients and 1.22±0.48 U/L for control group, P<0.001; ARE activity is 160.76±10.79 U/L for CRC patients). ARE levels showed a positive correlation with smoking status (P=0.04). PON1 activity was higher in colon carcinoma patients (135.95±19.3 U/L) rather than rectal carcinoma patients (97.08±5.24 U/L) but it was not statistically significant (P=0.72). CONCLUSION: Serum PON1 activity is increased in patients with CRC, and serum ARE levels showed a positive correlation with smoking status. PON1 activity was higher in colon carcinoma patients. There is no other study in literature investigating these activities for CRC patients. It should be reevaluated by larger clinical trials.
BACKGROUND: The aim of this study was to evaluate paraoxonase-1 (PON1) and arylesterase (ARE) activities and oxidative stress status in patients with colorectal carcinomas (CRC). MATERIALS AND METHODS: Thirty-three patients (20 male, 13 female) with CRC and 30 healthy controls were enrolled in the study. Blood samples were obtained from the CRCpatients before adjuvant therapy. Serum samples from CRCpatients and healthy controls were analyzed for PON1 and ARE activities. RESULTS: The PON1 and ARE activities of the patients with CRC were significantly higher compared to those of the control group (PON1 activity is 125.35±20.07 U/L for CRCpatients and 1.22±0.48 U/L for control group, P<0.001; ARE activity is 160.76±10.79 U/L for CRCpatients). ARE levels showed a positive correlation with smoking status (P=0.04). PON1 activity was higher in colon carcinomapatients (135.95±19.3 U/L) rather than rectal carcinomapatients (97.08±5.24 U/L) but it was not statistically significant (P=0.72). CONCLUSION: Serum PON1 activity is increased in patients with CRC, and serum ARE levels showed a positive correlation with smoking status. PON1 activity was higher in colon carcinomapatients. There is no other study in literature investigating these activities for CRCpatients. It should be reevaluated by larger clinical trials.
Authors: Cari M Kitahara; Sonja I Berndt; Amy Berrington de González; Helen G Coleman; Robert E Schoen; Richard B Hayes; Wen-Yi Huang Journal: J Clin Oncol Date: 2013-05-28 Impact factor: 44.544
Authors: Peter M Rothwell; F Gerald R Fowkes; Jill F F Belch; Hisao Ogawa; Charles P Warlow; Tom W Meade Journal: Lancet Date: 2010-12-06 Impact factor: 79.321
Authors: Jennifer Ose; Akke Botma; Yesilda Balavarca; Katharina Buck; Dominique Scherer; Nina Habermann; Jolantha Beyerle; Katrin Pfütze; Petra Seibold; Elisabeth J Kap; Axel Benner; Lina Jansen; Katja Butterbach; Michael Hoffmeister; Hermann Brenner; Alexis Ulrich; Martin Schneider; Jenny Chang-Claude; Barbara Burwinkel; Cornelia M Ulrich Journal: Cancer Med Date: 2018-05-29 Impact factor: 4.452
Authors: Stanislav Naryzhny; Natalia Ronzhina; Elena Zorina; Fedor Kabachenko; Nikolay Klopov; Victor Zgoda Journal: Int J Mol Sci Date: 2022-09-21 Impact factor: 6.208